Search

everythinglearnresearchcommunity

for

Search:↓

Testosterone replacement can help menopausal women with various symptoms, but should be used carefully and is not yet officially licensed in the UK for women.

Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

The skin's ability to produce hormones is linked to various skin conditions, and better understanding this process could lead to new treatments.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Sex hormones affect brain injury differently in males and females.

Some drugs can cause hair loss, change hair color and shape, or increase hair growth, and treatment may involve stopping the drug or using specific hair growth treatments.

People with polycystic ovary syndrome often have low levels of vitamin D.

Retinoic acid affects male and female muscle energy use and function differently.

Genetic counselors should be culturally skilled and aware of transgender patients' unique health risks and needs.

The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.

Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

Sex hormones affect hair and feather growth and may help manage alopecia and hormone-dependent cancers.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

CEC levels may be a useful marker for predicting prostate cancer progression.

Oral contraceptives lower testosterone levels in women, especially those with certain genetic traits, and may be linked to increased breast cancer risk.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

Gene variation affects prostate issues and hair loss.